Preclinical and Clinical Evaluation of Novel Agents for Noninvasive Imaging of Prostate Cancer

摘要

Imaging procedures play an important role in the current management of patients with prostate cancer. Despite advances in many of these methodologies, improvements are still needed, especially in the area of Nuclear Medicine. The radiodinated phospholipid ether analogs investigated under this grant represent a new class of radiopharmaceutical, which has provided excellent images of prostate tumors in animal models. Two of the newer analogs, namely NM- 404 and NM-412, were found to be significantly superior to the prototype agent, NM-324 in both the rat and mouse tumor models, while avoiding the high first pass clearance by the liver displayed by NM-324. NM-404 has been approved by the Food and Drug Administration as an Investigational New Drug (IND 62,703).